Oculis (NASDAQ:OCS) Trading Down 5.2% – Here’s Why

Oculis Holding AG (NASDAQ:OCS) was down 5.2% during mid-day trading on Friday . The stock traded as low as $29.45 and last traded at $29.38. Approximately 322,560 shares were traded during trading, a decline of 10% from the average daily volume of 356,983 shares. The stock had previously closed at $31.00.

Analyst Ratings Changes

Several analysts have recently issued reports on OCS shares. Needham & Company LLC upped their target price on shares of Oculis from $40.00 to $46.00 and gave the company a “buy” rating in a research report on Tuesday, May 12th. HC Wainwright upped their target price on shares of Oculis from $44.00 to $47.00 and gave the company a “buy” rating in a research report on Tuesday, May 12th. Wall Street Zen cut shares of Oculis from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Stifel Nicolaus upped their target price on shares of Oculis from $40.00 to $50.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Oculis in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Oculis presently has an average rating of “Moderate Buy” and an average price target of $49.38.

Oculis Price Performance

The company has a market capitalization of $1.71 billion, a P/E ratio of -13.85 and a beta of 0.38. The firm’s fifty day moving average is $27.48 and its 200 day moving average is $24.86. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.18 and a current ratio of 5.18.

Oculis (NASDAQ:OCS) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.14). The firm had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.25 million. Oculis had a negative net margin of 8,460.67% and a negative return on equity of 56.78%. As a group, analysts predict that Oculis Holding AG will post -2.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Oculis

A number of hedge funds have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. boosted its stake in shares of Oculis by 100.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock valued at $40,000 after purchasing an additional 1,000 shares in the last quarter. Aventura Private Wealth LLC purchased a new stake in Oculis during the fourth quarter valued at approximately $80,000. Koshinski Asset Management Inc. purchased a new stake in Oculis during the first quarter valued at approximately $238,000. Millennium Management LLC purchased a new stake in Oculis during the fourth quarter valued at approximately $312,000. Finally, Marshall Wace LLP purchased a new stake in Oculis during the second quarter valued at approximately $393,000. 22.30% of the stock is currently owned by institutional investors.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.